Stock TSVT 2SEVENTY BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages 2seventy bio, Inc.

Equities

TSVT

US9013841070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
4.38 USD -1.24% Intraday chart for 2seventy bio, Inc. -7.98% +2.58%
May. 08 Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M MT
May. 08 Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US FDA mandates label updates on CAR-T cancer therapies
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication
Bristol Myers : la FDA valide Abecma dans le myélome multiple
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
U.S. FDA allows expanded use of Bristol Myers' cell therapy
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc..
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc. for $15 million.
2seventy bio, Inc. Announces Board Appointments
Top Premarket Gainers
FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies
2seventy bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
2seventy bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Bristol-Myers Squibb, 2seventy bio's Supplemental BLA Application for Abecma Expected to be Reviewed by US FDA March 15
Bristol Myers : la FDA va étudier Abecma comme soin du myélome
Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
2seventy bio to Sell Investigational Cell Therapies to Regeneron Amid Restructuring
2seventy bio, Inc. Announces CEO Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSVT Stock
  4. News 2seventy bio, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW